MetaCap

InspireMD (NSPR) vs PAVmed (PAVM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.

Summary

InspireMD (NSPR) has outperformed PAVmed (PAVM) over the past year, losing 80.3% versus a loss of 81.1%. Over five years, NSPR leads with a -88.7% price change compared with -99.9% for PAVM. InspireMD is the larger company by market cap ($22.3 million vs $21.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

NSPR-80.33%PAVM-81.12%
+22%-32%-86%
Oct 8, 20251 yearOct 8, 2026
NSPR-87.72%PAVM-99.93%
+14%-46%-105%
Oct 4, 20215 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

NSPR versus PAVM key metrics
MetricNSPRPAVM
Share price$0.48$2.69
Market cap$22.31M$21.51M
1-day change-6.61%-1.82%
YTD return-73.03%-59.43%
1-year return-80.33%-81.12%
5-year return-88.68%-99.90%
EPS (TTM)$-0.62$-14.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.54$28.44
52-week low$0.46$2.60
Distance from 52-week high-81.10%-90.54%
Analyst consensusnonenone
Avg. price target upside+593.75%+1256.88%
Average volume79.31K30.34K
Shares outstanding46.49M8.00M
Employees12741
SectorHealthcareHealthcare
IndustryMedical DevicesMedical Devices

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About InspireMD

NSPR stock →

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions.

Healthcare · Medical Devices · 127 employees

About PAVmed

PAVM stock →

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States.

Healthcare · Medical Devices · 41 employees

NSPR vs PAVM FAQ

Which is bigger, InspireMD or PAVmed?

InspireMD (NSPR) is larger, with a market capitalization of $22.31M compared with $21.51M for PAVmed (PAVM).

Which stock has performed better over the past year, NSPR or PAVM?

NSPR returned -80.33% over the past 12 months, compared with -81.12% for PAVM (price return, excluding dividends). Past performance does not predict future results.

Are InspireMD and PAVmed in the same industry?

Yes. Both are classified in the Medical Devices industry within the Healthcare sector.

More comparisons